A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
NCT00987935 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134
Last updated 2016-03-10
Summary
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
Conditions
- Carcinoma, Hepatocellular
Interventions
- DRUG
-
400 mg twice daily
- DRUG
-
BIBF 1120
Twice daily
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-10-31
- Primary Completion
- 2014-07-31
- Completion
- 2016-01-31
Countries
- South Korea
- Taiwan
Study Locations
More Related Trials
-
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
NCT02575339 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
NCT00920192 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
NCT01009593 ·Status: TERMINATED ·Phase: PHASE3
-
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
NCT03893695 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
NCT02354898 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
NCT02279719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
NCT05897138 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
NCT02178358 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
NCT01204177 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
NCT02966821 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
NCT00813293 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT02953743 ·Status: COMPLETED ·Phase: PHASE1
-
Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
NCT01908322 ·Status: COMPLETED
-
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
NCT01932385 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
NCT01108705 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
NCT02240433 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
NCT01942083 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
NCT02645981 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.
NCT07233759 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
NCT01192971 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
NCT00517920 ·Status: COMPLETED ·Phase: PHASE2
-
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
NCT04392700 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
NCT03794440 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
NCT01232296 ·Status: COMPLETED ·Phase: PHASE2
-
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
NCT04044651 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3